Islatravir

Islatravir (also known as MK-8591 or EFdA) is an experimental antiretroviral medication in development by Merck & Co. for the treatment and prevention of HIV/AIDS. It is a nucleoside reverse transcriptase translocation inhibitor (NRTTI).

Mechanism of action

Islatravir is a nucleoside reverse transcriptase translocation inhibitor (NRTTI). It works by inhibiting the reverse transcriptase enzyme, an essential protein for the replication of HIV. Unlike other nucleoside reverse transcriptase inhibitors (NRTIs), islatravir causes the DNA chain to pause, rather than immediately terminate, allowing it to bind more tightly to the reverse transcriptase enzyme.

Development and clinical trials

Islatravir is currently in phase II/III clinical trials for both the treatment and prevention of HIV/AIDS. Early results from these trials have shown promise, with islatravir demonstrating potent antiretroviral activity and a good safety profile.

Potential advantages

Islatravir has several potential advantages over existing antiretroviral medications. It has a long half-life, which could allow for less frequent dosing. It also has a high barrier to resistance, meaning it could be effective in patients who have developed resistance to other antiretroviral medications.

See also

• Antiretroviral medication
• HIV/AIDS
• Merck & Co.

Islatravir Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.

Translate to: East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski